Crescent Biopharma (CBIO) Other Operating Expenses (2024 - 2025)
Crescent Biopharma (CBIO) reported Other Operating Expenses of $16.8 million for Q4 2025, up 1273.69% on a QoQ basis from $1.2 million in Q3 2024.
Crescent Biopharma (CBIO) has 2 years of Other Operating Expenses data on file, last reported at $16.8 million in Q4 2025.
- Quarterly Other Operating Expenses changed N/A year-over-year to $16.8 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $16.8 million (up 1273.69% YoY) and the FY2024 annual result came in at $1.2 million, changed N/A from the prior year.
- Other Operating Expenses rose to $16.8 million in Q4 2025 per CBIO's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $16.8 million in Q4 2025 and bottomed at $1.2 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.83 Mn |
| Sep 30, 2024 | 1.22 Mn |